By Rob Lenihan TheStreet.com Staff Reporter 1/10/2006 2:24 PM EST Click here for more stories by Rob Lenihan
Shares of Exact Sciences (EXAS:Nasdaq - commentary - research - Cramer's Take) rose nearly 50% after the Marlborough, Mass., genomics company said improvements to its technology demonstrated sensitivity in excess of 80% for detecting colorectal cancer in a recent research study. Exact Sciences was surging $1.28, or 49.4%, to $3.87.
Genzyme (GENZ:Nasdaq - commentary - research - Cramer's Take) dropped after the Cambridge, Mass., biotech company said its fourth-quarter sales would miss analysts' expectations. Genzyme said revenue will be $722 million in the quarter, up from $591 million a year earlier. Analysts surveyed by Thomson First Call were expecting revenue of $729.9 million. Shares of Genzyme were down $1.90, or 2.5%, to $73.14.
1. Cisco Turns Traffic Cop 2. Stern Stocks Up on Sirius 3. Google: Runaway Bull 4. Buyout Talk Buoys BMC 5. Top 10 Turnarounds for 2006, Part 2
DJ Orthopedics (DJO:NYSE - commentary - research - Cramer's Take) moved higher after the Vista, Calif., medical-supply company said fourth-quarter sales were about $75 million, up 10% from a year ago. Shares of DJ Orthopedics were gaining $2.19, or 7.7%, to $30.80.
Accentia Biopharmaceuticals (ABPI:Nasdaq - commentary - research - Cramer's Take) jumped after the Tampa, Fla., company said data from a Phase 2 clinical trial of BiovaxID, its lymphoma vaccine, were encouraging. Shares of Accentia were gaining $1.47, or 27.5%, or $6.82.
CryoLife (CRY:NYSE - commentary - research - Cramer's Take) rose after the Kennesaw, Ga., company, which provides tissues for transplants, raised its 2006 sales guidance. The company said it expects this year's sales to range from $74 million to $77 million, an increase from the previous estimate of $72 million to $76 million. CryoLife was up 89 cents, or 28.7%, to $3.99 in recent trading.
Market Data 
Markets 
AI
